Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - abilify
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp083329ed80f9e5f1c8e6dd49ed81d7aa
identifier: http://ema.europa.eu/identifier
/EU/1/13/882/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-083329ed80f9e5f1c8e6dd49ed81d7aa
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/13/882/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - abilify
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Abilify Maintena contains the active substance aripiprazole and belongs to a group of medicines called antipsychotics. It is used to treat schizophrenia - a disease with symptoms such as hearing, seeing or sensing things which are not there, suspiciousness, mistaken beliefs, incoherent speech and behaviour and emotional flatness. People with this condition may also feel depressed, guilty, anxious or tense.
Abilify Maintena is intended for adult patients with schizophrenia who are sufficiently stabilised during treatment with oral aripiprazole.
Do not use Abilify Maintena
Warnings and precautions Talk to your doctor or nurse before you are given Abilify Maintena.
Suicidal thoughts and behaviours have been reported during aripiprazole treatment. Tell your doctor immediately if you are having any thoughts or feelings about hurting yourself.
Before treatment with Abilify Maintena, tell your doctor if you suffer from
If you notice you are gaining weight, develop unusual movements, experience sleepiness that interferes with normal daily activities, any difficulty in swallowing or have allergic symptoms, please talk to your doctor immediately.
Tell your doctor if you or your family/carer notices that you are developing urges or cravings to behave in ways that are unusual for you and you cannot resist the impulse, drive or temptation to carry out certain activities that could harm yourself or others. These are called impulse control disorders and can include behaviours such as addictive gambling, excessive eating or spending, an abnormally high sex drive or preoccupation with an increase in sexual thoughts or feelings. Your doctor may need to adjust or stop your dose.
Aripiprazole may cause sleepiness, fall in blood pressure when standing up, dizziness and changes in your ability to move and balance, which may lead to falls. Caution should be taken, particularly if you are an elderly patient or have some debility.
Children and adolescents Do not use this medicine in children and adolescents under 18 years of age. It is not known if it is safe and effective in these patients.
Other medicines and Abilify Maintena Tell your doctor if you are taking, have recently taken or might take any other medicines.
Blood pressure-lowering medicines: Abilify Maintena may increase the effect of medicines used to lower the blood pressure. Be sure to tell your doctor if you take a medicine to keep your blood pressure under control.
Receiving Abilify Maintena with some medicines may mean the doctor will need to change your dose of Abilify Maintena or the other medicines. It is especially important to mention the following to your doctor:
These medicines may increase the risk of side effects or reduce the effect of Abilify Maintena; if you get any unusual symptom taking any of these medicines together with Abilify Maintena, you should see your doctor.
Medicines that increase the level of serotonin are typically used in conditions including depression, generalised anxiety disorder, obsessive-compulsive disorder (OCD) and social phobia as well as migraine and pain:
These medicines may increase the risk of side effects; if you get any unusual symptom taking any of these medicines together with Abilify Maintena, you should see your doctor.
Abilify Maintena with alcohol Alcohol should be avoided.
Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before receiving this medicine.
You should not be given Abilify Maintena if you are pregnant unless you have discussed this with your doctor. Be sure to tell your doctor immediately if you are pregnant, think you may be pregnant, or if you are planning to become pregnant.
The following symptoms may occur in new-born babies, of mothers that have received Abilify Maintena in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding.
If your baby develops any of these symptoms you need to contact your doctor.
If you are receiving Abilify Maintena, your doctor will discuss with you whether you should breast- feed considering the benefit to you of your therapy and the benefit to your baby of breast-feeding. You should not do both. Talk to your doctor about the best way to feed your baby if you are receiving Abilify Maintena.
Driving and using machines Dizziness and vision problems may occur during treatment with this medicine (see section 4). This should be considered in cases where full alertness is required, e.g., when driving a car or handling machines.
Abilify Maintena contains sodium This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially sodium- free .
Abilify Maintena comes as a powder which your doctor or nurse will make into a suspension.
Your doctor will decide on the dose of Abilify Maintena that is right for you. The recommended starting dose is 400 mg unless your doctor decided to give you a lower starting or follow up dose (300 mg, 200 mg or 160 mg).
There are two ways to start Abilify Maintena, your doctor will decide which way is right for you.
aripiprazole by mouth is continued for 14 days after the first injection.
After that, treatment is given with injections of Abilify Maintena unless your doctor tells you otherwise.
Your doctor will give it to you as a single injection into the gluteal or deltoid muscle (buttock or shoulder) every month. You may feel a little pain during the injection. Your doctor will alternate the injections between your right and left side. The injections will not be given intravenously.
If you are given more Abilify Maintena than you should This medicine will be given to you under medical supervision; it is therefore unlikely that you will be given too much. If you see more than one doctor, be sure to tell them that you are receiving Abilify Maintena.
Patients who have been given too much aripiprazole have experienced the following symptoms:
Other symptoms may include:
Contact your doctor or hospital immediately if you experience any of the above.
If you miss an injection of Abilify Maintena It is important not to miss your scheduled dose. You should be given an injection every month but not before the 26 days has passed from the last injection. If you miss an injection, you should contact your doctor to arrange your next injection as soon as you can.
If you stop receiving Abilify Maintena Do not stop your treatment just because you feel better. It is important that you carry on receiving Abilify Maintena for as long as your doctor has told you to.
If you have any further questions on the use of this medicine, ask your doctor or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Tell your doctor immediately if you have any of the following serious side effects:
The side effects listed below may also occur after receiving Abilify Maintena.
Common side effects (may affect up to 1 in 10 people):
Uncommon side effects (may affect up to 1 in 100 people):
The following side effects have been reported since the marketing of oral aripiprazole but the frequency for them to occur is not known (frequency cannot be estimated from the available data):
Reporting of side effects If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and the vial. The expiry date refers to the last day of that month.
Do not freeze.
The reconstituted suspension should be used immediately but may be stored below 25 C for up to 4 hours in the vial. Do not store the reconstituted suspension in the syringe.
What Abilify Maintena contains
The active substance is aripiprazole. Each vial contains 300 mg aripiprazole. After reconstitution each mL of suspension contains 200 mg aripiprazole. Each vial contains 400 mg aripiprazole. After reconstitution each mL of suspension contains 200 mg aripiprazole.
The other ingredients are Powder Carmellose sodium, mannitol, sodium dihydrogen phosphate monohydrate, sodium hydroxide Solvent Water for injections
What Abilify Maintena looks like and contents of the pack Abilify Maintena is a powder and solvent for prolonged-release suspension for injection.
Abilify Maintena comes as a white to off-white powder in a clear glass vial. Your doctor or nurse will make it into a suspension that will be given as an injection using the vial of solvent for Abilify Maintena that comes as a clear solution in a clear glass vial.
Single pack Each single pack containing one vial of powder, 2 mL vial of solvent, one 3 mL luer lock syringe with pre-attached 38 mm (1.5 inch) 21 gauge, hypodermic safety needle with needle protection device, one 3 mL disposable syringe with luer lock tip, one vial adapter and three hypodermic safety needles: one 25 mm (1 inch) 23 gauge, one 38 mm (1.5 inch) 22 gauge and one 51 mm (2 inch) 21 gauge.
Multipack Bundle pack of 3 single packs.
Not all pack sizes may be marketed.
Marketing Authorisation Holder Otsuka Pharmaceutical Netherlands B.V. Herikerbergweg 1101 CT, Amsterdam Netherlands
Manufacturer H. Lundbeck A/S Ottiliavej 9, 2500 Valby Denmark
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Belgi /Belgique/Belgien Lundbeck S.A./N.V. T l/Tel: +32 2 535 79 Lietuva H. Lundbeck A/S Tel: +45 36301
Lundbeck Export A/S Representative Office Tel: +359 2 962 4Luxembourg/Luxemburg Lundbeck S.A. T l: +32 2 535 79 esk republika Lundbeck esk republika s.r.o. Tel: +420 225 275 Magyarorsz g Lundbeck Hungaria Kft. Tel: +36 1 4369Danmark Otsuka Pharma Scandinavia AB Tel: +46 8 54528Malta H. Lundbeck A/S Tel: +45 36301Deutschland Otsuka Pharma GmbH Tel: +49 69 1700Nederland Lundbeck B.V. Tel: +31 20 697 1Eesti H. Lundbeck A/S Tel: +45 36301Norge Otsuka Pharma Scandinavia AB Tel: +46 8 54528
Lundbeck Hellas S.A. : +30 210 610 5 sterreich Lundbeck Austria GmbH Tel: +43 1 266 91 Espa a Otsuka Pharmaceutical S.A. Tel: +34 93 208 10 Polska Lundbeck Poland Sp. z o. o. Tel.: +48 22 626 93 France Otsuka Pharmaceutical France SAS T l: +33 (0)1 47 08 00 Portugal Lundbeck Portugal Lda Tel: +351 21 00 45 Hrvatska Lundbeck Croatia d.o.o. Tel.: +385 1 644 82 Rom nia Lundbeck Romania SRL Tel: +40 21319 88 Ireland Lundbeck (Ireland) Limited Tel: +353 1 468 9Slovenija Lundbeck Pharma d.o.o. Tel.: +386 2 229 4 sland Vistor hf. S mi: +354 535 7Slovensk republika Lundbeck Slovensko s.r.o. Tel: +421 2 5341 42 Italia Otsuka Pharmaceutical Italy S.r.l Tel: +39 02 00 63 27 Suomi/Finland Otsuka Pharma Scandinavia AB Tel: +46 8 54528
Lundbeck Hellas A.E .: +357 22490Sverige Otsuka Pharma Scandinavia AB Tel: +46 8 54528Latvija H. Lundbeck A/S Tel: +45 36301United Kingdom (Northern Ireland) Otsuka Pharmaceutical Netherlands B.V. Tel: +31 (0) 20 85 46 This leaflet was last revised in {MM/YYYY}.
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-083329ed80f9e5f1c8e6dd49ed81d7aa
Resource Composition:
Generated Narrative: Composition composition-en-083329ed80f9e5f1c8e6dd49ed81d7aa
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/13/882/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - abilify
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp083329ed80f9e5f1c8e6dd49ed81d7aa
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp083329ed80f9e5f1c8e6dd49ed81d7aa
identifier:
http://ema.europa.eu/identifier
/EU/1/13/882/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en